First‐line pembrolizumab or atezolizumab monotherapy is an effective regimen in patients with NSCLC with high PD‐L1 expression in tumor cells; however, it is unclear whether ICI monotherapy or combination immunotherapy is beneficial.10, 22. Here, CD274 is linked to non-small cell lung carcinoma.